Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Dec 07, 2022 10:51am
154 Views
Post# 35156200

RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stock

RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stockWell today we are continuing to experience these manipulative tactics in action. 

Barking dogs are out trying to create as much manipulative noise as possible to drown out rational and relevant information. Numerous newly created posters out to try to distract and distort by using the manipulative tactic of empty questioning and diversionary posts. Just barking dogs.

All others can take comfort in knowing that in the challenge of overcoming the hypoxia that characterizes solid tumors and a hostile TME, ONCY's oncolytic virus pelareorep (reovirus) is able to down-regulate HIF-1α signaling, resulting in HIF-1α inhibition, and by doing so is able to convert an otherwise aggressive and hypoxic tumor microenvironment (TME) into one that can promote T cell function, and is conducive for immune checkpoint inhibition, as the AWARE-1 study is demonstrating. 
<< Previous
Bullboard Posts
Next >>